Neurocrine biosciences to present new data analyses for crinecerfont in adults with classic congenital adrenal hyperplasia at endo 2021

San diego, march 20, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present additional positive data from its phase ii cahlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 (crf1) receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency (21-ohd), at endo 2021, the endocrine society's annual meeting, on march 20–23, 2021. these new analyses, based on data from seven male subjects with classic cah receiving crinecerfont, demonstrate dose-dependent decreases in androstenedione (a4), a key marker of cah control and precursor to testosterone, with similar dose-dependent decreases in the a4 to testosterone ratio.
NBIX Ratings Summary
NBIX Quant Ranking